Quality by Design: Reagents and Support for hPSC-Derived Cell and Gene Therapies

Each year, more human pluripotent stem cell-derived (hPSC-derived) therapies move towards the clinic, and STEMCELL is committed to supporting researchers from discovery to clinical application. In this Innovation Showcase from ISSCR 2021, Lynn Csontos will demonstrate how we build quality into our products, processes, and policies to support your project timing, product quality, and overall vision. Kimberly Snyder will then present data that shows how TeSR™-AOF, a novel animal origin-free (AOF) hPSC maintenance medium, can support optimized cell quality, improved performance and reproducibility across all cell lines.

Each year, more human pluripotent stem cell-derived (hPSC-derived) therapies move towards the clinic, and STEMCELL is committed to supporting researchers from discovery to clinical application. In this Innovation Showcase from ISSCR 2021, Lynn Csontos will demonstrate how we build quality into our products, processes, and policies to support your project timing, product quality, and overall vision. Kimberly Snyder will then present data that shows how TeSR™-AOF, a novel animal origin-free (AOF) hPSC maintenance medium, can support optimized cell quality, improved performance and reproducibility across all cell lines.

As a supporter of, and participant in, ISSCR’s 2021 Annual Meeting, we share with you our Innovation Showcase presentation at #ISSCR2021.
This presentation does not represent an endorsement from or support of the ISSCR.
Publish Date: August 16, 2021